Aliskiren-based stepped-care treatment algorithm provides effective blood pressure control.

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Hypertension Management

Background:

• Recent hypertension guidelines advocate individualized stepped-care treatment for mild-to-moderate cases.
• Achieving blood pressure (BP) targets is crucial for patient outcomes.

Purpose of the Study:

• To evaluate the probability of achieving BP targets using an aliskiren-based stepped-care regimen.
• To assess the efficacy and tolerability of incremental add-on therapy in hypertension management.

Main Methods:

• A 24-week, open-label, non-comparator study in mild-to-moderate hypertensive patients.
• Sequential 4-week treatment periods with aliskiren, followed by hydrochlorothiazide (HCTZ), and amlodipine if needed.
• Primary endpoint: cumulative probability of patients achieving target BP.

Main Results:

• 232 out of 256 (90.6%) patients completed the study.
• The estimated cumulative probability of reaching BP target was 86.12% at study endpoint.
• The stepped-care regimen was well tolerated at maximal recommended doses.

Conclusions:

• An aliskiren-based stepped-care regimen, incorporating HCTZ and amlodipine, effectively achieves BP goals in approximately 90% of mild-to-moderate hypertensive patients.
• This treatment strategy demonstrates significant efficacy and good tolerability for hypertension management.